Scroll Top

FREE CONSULT

No Fees Unless You Collect

Sidley Represented OnCusp Therapeutics in the Oversubscribed US$100 Million Series A Financing

Sidley represented OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, in the oversubscribed US$100 million (more than RMB700 million) Series A financing round, which was co-led by Novo Holdings, OrbiMed, and F-Prime Capital, alongside Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture, BioTrack Capital, and others.The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. Additionally, the capital will aid in expanding the OnCusp portfolio and team.
The Sidley team was led by partners Ruchun Ji (Shanghai) and Geoffrey Levin (New York). Other team members included partners Eric Wolf (New York) and James Mendenhall (Washington, D.C.), managing associates Yahel Kaplan and Joel Lifshitz (New York), senior managing associate Carys Golesworthy (Washington, D.C.), associate Rui Liu (Shanghai), and law clerk Milly Kim (New York).

Powered by WPeMatico

Related Posts